FundComb

Investment and M&A transaction comps

Biotech & Pharma Investment & M&A Transaction Comps

Biotech, pharma, therapeutics, platform technology and life-sciences asset transactions. Revenue and EBITDA multiples are shown where meaningful; milestone, royalty, stage and asset-basis notes matter more for many pre-commercial deals.

Consumer CPG Beauty Supplements Food & Beverage Healthcare Biotech
11
Reviewed transactions
6
With price data
5.2x
Median EV or valuation / revenue
11.0x
Median EV or valuation / EBITDA
Year Transactions Priced Median EV or valuation / revenue Median EV or valuation / EBITDA
2026 4 2 - -

Sortable transaction comps

Biotech transaction table

Filter transactions

Narrow the table without crowding the main view.

Clear all filters

Rows with reported value

1 / 1

Acquisition EV, USD

USD 435M

Investment EV, USD

-

Median EV / revenue

-

Columns

Show columns

Select up to 12 rows across filters and pages, then share or export the set.

1 shown of 1 matching transactions. Click any transaction row for more detail.

Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately.

Select for comparison
2026-08-18 LEO Pharma 435 - -
PharmaTherapeutics
+2
DermatologyRare Disease
FundComb transaction comps are informational only. Prices are shown as estimated enterprise value where available, with USD used as the default sorting currency; revenue and EBITDA multiples are shown where available. Values may be estimated, rumored, incomplete or derived from public information and should not be relied upon as financial, investment or valuation advice.